Crescent Biopharma, Inc. (CBIO)

NASDAQ: CBIO · Real-Time Price · USD
15.00
-0.29 (-1.90%)
At close: Jul 8, 2025, 4:00 PM
15.09
+0.09 (0.60%)
After-hours: Jul 8, 2025, 4:00 PM EDT
-1.90%
Market Cap 224.31M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 14.95M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 91,309
Open 15.52
Previous Close 15.29
Day's Range 15.00 - 15.60
52-Week Range 11.06 - 21.40
Beta n/a
Analysts Strong Buy
Price Target 25.00 (+66.67%)
Earnings Date Aug 23, 2025

About CBIO

Crescent Biopharma, Inc. operates as a biotechnology company dedicated to advancing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors. The company was incorporated in 2024 and is based in USA. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 4
Stock Exchange NASDAQ
Ticker Symbol CBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for CBIO stock is "Strong Buy." The 12-month stock price target is $25.0, which is an increase of 66.67% from the latest price.

Price Target
$25.0
(66.67% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors

15 hours ago - GlobeNewsWire

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001

22 days ago - GlobeNewsWire

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, In...

4 weeks ago - Business Wire

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to a...

5 weeks ago - GlobeNewsWire

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics,...

7 weeks ago - Business Wire

Crescent Biopharma Appoints David Lubner to Board of Directors

Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology com...

2 months ago - GlobeNewsWire

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D.

3 months ago - GlobeNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

NEW YORK , March 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...

Other symbols: CMRX
4 months ago - PRNewsWire

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 b...

4 months ago - GlobeNewsWire

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass. , Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc...

8 months ago - PRNewsWire

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been...

8 months ago - Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...

Other symbols: PFIE
9 months ago - PRNewsWire

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc. (“Crescent”), a privately held biotechnol...

9 months ago - Business Wire

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

9 months ago - Business Wire

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

1 year ago - Business Wire

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

1 year ago - Business Wire

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory dis...

1 year ago - Business Wire

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

GlycoMimetics, Inc. (NASDAQ:GLYC) Corporate Update Call May 6, 2024 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer ...

1 year ago - Seeking Alpha

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

1 year ago - Business Wire

GlycoMimetics: Is No News Bad News?

GlycoMimetics is a biotech company focusing on developing a targeted therapy for acute myeloid leukemia. GLYC's lead candidate, uproleselan, has shown promising results in early-stage clinical trials ...

1 year ago - Seeking Alpha

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, ...

1 year ago - Business Wire

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

1 year ago - Business Wire

GlycoMimetics Can Become A Game Changer In Blood Cancers

GlycomiMetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. AML is a disease with a poor p...

1 year ago - Seeking Alpha

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on We...

1 year ago - Business Wire